Margaretta Colangelo, a partner at Deep Knowledge Ventures, mentioned in her recent article that although pharmaceutical companies spend more than $172 billion annually on research and development, more than 90% of the molecules discovered using traditional techniques are in human clinical trials. Failure. Moreover, 75% of newly approved drugs cannot afford development costs, and some analysts predict that the return on investment (ROI) of drug development may be zero by 2020. If we feel that this prediction has a great chance to become a reality, then we should regard artificial intelligence (AI) as a life-saving savior in the field of pharmaceutical R&D. Artificial intelligence also provides valuable choices for some patients.
Top-of-the-line artificial intelligence interconnection between drug discovery and drug development in pharmaceutical and technology companies (Figure: DKA)
Leading companies
In this life and death game, some companies tried to test the limits in the unknown. Deep Knowledge Analytics (DKA) is a subsidiary of DeepTech Ventures, a focus on DeepTech's investment fund. DKA Globally 1000 AI Healthcare (Healthcare Artificial Intelligence) company that specializes in the core of the scientific research and development company points out. According to DKA, the entry threshold for the artificial intelligence healthcare industry is lower than for artificial intelligence drug discovery, and these artificial intelligence healthcare companies can achieve real results with less capital and fewer highly specialized employees. Drug Discovery's AI requires a higher level of traditional biopharmaceutical science (biochemistry, biology, biomedical, etc.) and core AI technology. Bringing new AI-identified drugs to the market requires a “complete stackâ€, and the company needs a very strong, highly professional team and a sufficient number of experts with personal expertise to achieve a complete stack.
Even investors are having difficulty entering the industry because the minimum level of expertise required is relatively high. Investment fund companies rarely have a real understanding of the content, causes and methods of the industry and the parameters needed to make sound investment decisions in the industry. There may be less than 20 funds in 260 investment fund companies that fund 125 active artificial intelligence drug discovery companies.
Drug Discovery AI Experts Top 100 (Photo: DKA)
Hard competition, but the winner harvests money and glory
Perhaps in the next few years, some companies will exert a strong influence in the pharmaceutical industry, and thus achieve unprecedented breakthroughs in drug development. It took less than 200 years from ointment to artificial intelligence, and the development during the period fundamentally changed the quality of life of healthcare and patients. However, in recent decades, it has been widely believed that we have fallen into a stagnant situation, and every new step requires a lot of effort. We hope that AI will push healthcare to new heights in drug development. Still, some stars will disappear and new stars will appear, which is the law of physics. We know this and then relieved when we see the birth of a new star.
Pet Massager,Cat Massage,Dog Massage,Pet Groomer Tools
Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizonscares.com